#None #AusperBio #AHB-137 #Chronic Hepatitis B

AusperBio's Groundbreaking Results in Fighting Chronic Hepatitis B

In a significant breakthrough for hepatitis B treatment, AusperBio Therapeutics has presented findings showing that its investigational drug, AHB-137, can maintain a functional cure for up to 15 months after halting all treatment for chronic hepatitis B (CHB). Released during two pivotal presentations at The Liver Meeting® 2026, this data could reshape the future of CHB therapies.

Hepatitis B affects around 240 million people globally, leading to serious health complications like cirrhosis and liver cancer. Current nucleos(t)ide analog (NA) therapies often require lifelong adherence, as they primarily manage the virus rather than eradicate it. This context sets the stage for AusperBio's AHB-137, developed using their proprietary Med-Oligo™ antisense oligonucleotide (ASO) technology, aimed at offering patients a more definitive solution to CHB.

Key Findings and Implications

AusperBio's study reports several compelling outcomes:

• - Treatment-naïve Participants: Out of 7 individuals who responded completely to AHB-137 after a 16-week course, 6 continued to show signs of a functional cure 15 months post-treatment, illustrating the drug’s potential as a finite-duration therapy. One individual did experience a viral rebound.
• - NA-treated Participants: Among 17 evaluable patients, a remarkable 16 maintained their functional cure after a year, and 9 upheld this even at the 15-month mark. Throughout this follow-up phase, none required re-initiation of antiviral treatments, which marks a promising breakthrough for those accustomed to lifelong therapies.

No Adverse Events Recorded

The safety profile of AHB-137 appears equally reassuring; no severe relapses or new safety signals were noted during the follow-up, which encompassed both cohorts of treated participants. Guofeng Cheng, CEO of AusperBio, emphasized the importance of these findings: “A functional cure only matters if it lasts after treatment stops.”

Study Validation and Future Directions

The ongoing Phase 3 trial in China, alongside growing global research efforts, positions AHB-137 as a leading candidate in the quest for an effective finite-duration treatment for CHB. Experts like Professor Jinlin Hou and Professor Junqi Niu, principal investigators in the study, reaffirmed the clinical promise of AHB-137, highlighting its capacity to potentially shift the treatment paradigm for chronic hepatitis B patients.

Participants from the study were assessed for their responses, categorized as either complete or partial responders, based on established criteria involving hepatitis B surface antigen (HBsAg) and HBV DNA levels. The criteria for a functional cure were particularly stringent, requiring significant suppression of viral markers for an extended duration without treatment intervention.

Understanding AHB-137: A New Hope for Patients

AHB-137 aims to inhibit HBV replication and restore immune response to combat the virus. The recognition of this treatment’s effectiveness marks a possible transition in managing CHB, transitioning from the requirement of ongoing therapy to a more definitive and time-limited treatment approach. With national and global implications, patients and stakeholders eagerly await the continuation of research validating these initial findings.

Conclusion

As the landscape of chronic hepatitis B therapy evolves, AusperBio’s AHB-137 represents a significant leap towards establishing a lasting functional cure. By potentially offering a finite treatment solution, it not only aims to alleviate the burden of lifelong medication but also enhances the quality of life for millions affected by hepatitis B worldwide. Continuous evaluation and future studies will be critical as the medical community watches closely the impacts of this innovative therapy on global health.